You are here

Final Approval for Pergolide Announced

MIAMI – September 4, 2003 – IVAX Corporation (AMEX: IVX, LSE: IVX.L) announced today that it has received final approval for its Abbreviated New Drug Application (ANDA) for pergolide mesylate tablets in .05 mg, .25 mg and 1 mg dosage strengths and has begun marketing these tablets through the company’s wholly owned subsidiary, IVAX Pharmaceuticals, Inc.

Pergolide mesylate is the generic equivalent of Permax® tablets marketed by Amarin Corporation PLC for use as an adjunctive treatment in connection with Parkinson’s disease. U.S. sales of Permax during 2002 were approximately $50 million. Pergolide mesylate tablets’ active pharmaceutical ingredient is produced at IVAX’ facility in the Czech Republic, which will also be manufacturing the tablets.

Source: IVAX Corporation

Recent Headlines

Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission